Evommune, Inc. filed a current report on Form 8-K on September 23, 2026, disclosing that the company issued a press release announcing a late-breaker presentation of Phase 2a data for its EVO301 program in atopic dermatitis at the European Academy of Dermatology and Venereology 2026 Congress.

Key Highlights

  • Event reported: Evommune announced a late-breaker presentation of Phase 2a data for EVO301 in atopic dermatitis at the European Academy of Dermatology and Venereology 2026 Congress.
  • Filing date: The report was dated September 23, 2026, with that same date as the earliest event reported.
  • Disclosure type: The information was furnished under Item 7.01 Regulation FD Disclosure and is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.
  • Signed by: Luis Pena, President and Chief Executive Officer, signed the filing on behalf of Evommune, Inc.
  • Exchange listing: Common Stock ($0.0001 par value per share) trades on NYSE under the symbol EVMN.
  • Emerging growth company: Evommune indicated it is an emerging growth company and has not elected to opt out of the extended transition period for new or revised financial accounting standards.

Evommune Discloses EVO301 Phase 2a Atopic Dermatitis Data at EADV 2026

According to the filing, Evommune, Inc. (NYSE:EVMN) submitted a Form 8-K on September 23, 2026, reporting that it had issued a press release titled "Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology 2026 Congress." The press release, attached as Exhibit 99.1, was incorporated into the filing by reference.

The company disclosed that the information furnished under Item 7.01, including the press release exhibit, "shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934," meaning it does not carry the same legal weight as information formally filed with the Commission. The filing noted the information is also not automatically incorporated by reference into other filings under the Securities Act of 1933 or the Exchange Act, unless expressly stated.

Evommune is headquartered at 1891 Page Mill Road, Palo Alto, CA 94304. The company is incorporated in Delaware and carries Commission File Number 001-42938. Luis Pena, identified as President and Chief Executive Officer, signed the report on the company's behalf. No financial statements were included; the exhibits listed were the press release (Exhibit 99.1) and a Cover Page Interactive Data File (Exhibit 104).

What Was Disclosed

Evommune filed an 8-K on September 23, 2026, furnishing a press release under Regulation FD about a late-breaker Phase 2a data presentation for EVO301 in atopic dermatitis at the EADV 2026 Congress. No financial results were included in this filing.